Let me quote Cityslicker99 one more time: 

Big Pharma companies spend way more on projects with far smaller chances of success, with much smaller market potential and with success far into the future, than what they would do by buying RVX.  RVX should be a no brainer for them, even at US$2.5 billion price tag. 

I am surprised that there is no smoke yet on the fire of a buyer showing up.  Maybe this BT designation has changed the discussion.